Trial
NCT00574236
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.
Condition
Metastatic Breast Cancer
Intervention
PS-341, doxorubicin
Why stopped
no additional funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-13